nodes	percent_of_prediction	percent_of_DWPC	metapath
Conivaptan—CYP3A4—Estropipate—osteoporosis	0.0971	0.181	CbGbCtD
Conivaptan—CYP3A4—Calcitriol—osteoporosis	0.0971	0.181	CbGbCtD
Conivaptan—CYP3A4—Ergocalciferol—osteoporosis	0.0776	0.145	CbGbCtD
Conivaptan—CYP3A4—Raloxifene—osteoporosis	0.0648	0.121	CbGbCtD
Conivaptan—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0626	0.117	CbGbCtD
Conivaptan—CYP3A4—Cholecalciferol—osteoporosis	0.05	0.0934	CbGbCtD
Conivaptan—CYP3A4—Conjugated Estrogens—osteoporosis	0.0459	0.0858	CbGbCtD
Conivaptan—CYP3A4—Estradiol—osteoporosis	0.0403	0.0753	CbGbCtD
Conivaptan—CYP3A4—Drug Induction of Bile Acid Pathway—SLC51A—osteoporosis	0.0037	0.0484	CbGpPWpGaD
Conivaptan—AVPR2—G alpha (s) signalling events—PTH1R—osteoporosis	0.00352	0.0461	CbGpPWpGaD
Conivaptan—AVPR2—G alpha (s) signalling events—CALCR—osteoporosis	0.00352	0.0461	CbGpPWpGaD
Conivaptan—AVPR2—Vasopressin regulates renal water homeostasis via Aquaporins—ADCY5—osteoporosis	0.00224	0.0293	CbGpPWpGaD
Conivaptan—AVPR1A—G alpha (q) signalling events—MGLL—osteoporosis	0.00203	0.0265	CbGpPWpGaD
Conivaptan—AVPR2—Aquaporin-mediated transport—ADCY5—osteoporosis	0.00196	0.0256	CbGpPWpGaD
Conivaptan—AVPR2—G alpha (s) signalling events—PTH—osteoporosis	0.00185	0.0242	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—MGLL—osteoporosis	0.00182	0.0237	CbGpPWpGaD
Conivaptan—AVPR2—G alpha (s) signalling events—PTHLH—osteoporosis	0.00153	0.0201	CbGpPWpGaD
Conivaptan—AVPR2—G alpha (s) signalling events—CALCA—osteoporosis	0.00135	0.0177	CbGpPWpGaD
Conivaptan—Diarrhoea—Calcium Acetate—osteoporosis	0.00132	0.0034	CcSEcCtD
Conivaptan—Urinary tract infection—Risedronate—osteoporosis	0.00132	0.0034	CcSEcCtD
Conivaptan—Pneumonia—Pamidronate—osteoporosis	0.0013	0.00334	CcSEcCtD
Conivaptan—Mental disorder—Ibandronate—osteoporosis	0.00129	0.00334	CcSEcCtD
Conivaptan—Infestation—Pamidronate—osteoporosis	0.00129	0.00332	CcSEcCtD
Conivaptan—Infestation NOS—Pamidronate—osteoporosis	0.00129	0.00332	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—CALCR—osteoporosis	0.00129	0.0169	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—PTH1R—osteoporosis	0.00129	0.0169	CbGpPWpGaD
Conivaptan—Erythema—Ibandronate—osteoporosis	0.00129	0.00332	CcSEcCtD
Conivaptan—Malnutrition—Ibandronate—osteoporosis	0.00129	0.00332	CcSEcCtD
Conivaptan—AVPR2—GPCR ligand binding—PTH1R—osteoporosis	0.00128	0.0167	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—CALCR—osteoporosis	0.00128	0.0167	CbGpPWpGaD
Conivaptan—Confusional state—Etidronic acid—osteoporosis	0.00128	0.00329	CcSEcCtD
Conivaptan—Erythema—Calcitriol—osteoporosis	0.00126	0.00325	CcSEcCtD
Conivaptan—Infection—Etidronic acid—osteoporosis	0.00126	0.00324	CcSEcCtD
Conivaptan—Urinary tract infection—Pamidronate—osteoporosis	0.00125	0.00323	CcSEcCtD
Conivaptan—Urinary tract disorder—Ethinyl Estradiol—osteoporosis	0.00123	0.00318	CcSEcCtD
Conivaptan—Haematuria—Pamidronate—osteoporosis	0.00123	0.00317	CcSEcCtD
Conivaptan—Vomiting—Calcium Acetate—osteoporosis	0.00123	0.00316	CcSEcCtD
Conivaptan—Urethral disorder—Ethinyl Estradiol—osteoporosis	0.00122	0.00316	CcSEcCtD
Conivaptan—Anaemia—Alendronate—osteoporosis	0.00122	0.00315	CcSEcCtD
Conivaptan—Pollakiuria—Zoledronate—osteoporosis	0.00122	0.00315	CcSEcCtD
Conivaptan—Urinary tract disorder—Risedronate—osteoporosis	0.0012	0.0031	CcSEcCtD
Conivaptan—Oedema peripheral—Risedronate—osteoporosis	0.0012	0.00309	CcSEcCtD
Conivaptan—Urethral disorder—Risedronate—osteoporosis	0.00119	0.00308	CcSEcCtD
Conivaptan—Anaemia—Ibandronate—osteoporosis	0.00119	0.00306	CcSEcCtD
Conivaptan—Infestation NOS—Zoledronate—osteoporosis	0.00118	0.00304	CcSEcCtD
Conivaptan—Infestation—Zoledronate—osteoporosis	0.00118	0.00304	CcSEcCtD
Conivaptan—Hyperglycaemia—Conjugated Estrogens—osteoporosis	0.00115	0.00296	CcSEcCtD
Conivaptan—Urinary tract infection—Zoledronate—osteoporosis	0.00114	0.00295	CcSEcCtD
Conivaptan—Nausea—Calcium Acetate—osteoporosis	0.00114	0.00295	CcSEcCtD
Conivaptan—Urinary tract disorder—Pamidronate—osteoporosis	0.00114	0.00295	CcSEcCtD
Conivaptan—Urethral disorder—Pamidronate—osteoporosis	0.00113	0.00293	CcSEcCtD
Conivaptan—Infestation—Conjugated Estrogens—osteoporosis	0.00113	0.00292	CcSEcCtD
Conivaptan—Infestation NOS—Conjugated Estrogens—osteoporosis	0.00113	0.00292	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Estropipate—osteoporosis	0.00113	0.00292	CcSEcCtD
Conivaptan—Angiopathy—Ethinyl Estradiol—osteoporosis	0.00113	0.00292	CcSEcCtD
Conivaptan—Cardiac disorder—Risedronate—osteoporosis	0.00113	0.00291	CcSEcCtD
Conivaptan—Haematuria—Zoledronate—osteoporosis	0.00112	0.0029	CcSEcCtD
Conivaptan—Hypertension—Ibandronate—osteoporosis	0.00111	0.00286	CcSEcCtD
Conivaptan—Angiopathy—Risedronate—osteoporosis	0.0011	0.00285	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Raloxifene—osteoporosis	0.0011	0.00283	CcSEcCtD
Conivaptan—Mediastinal disorder—Risedronate—osteoporosis	0.0011	0.00283	CcSEcCtD
Conivaptan—Mental disorder—Ethinyl Estradiol—osteoporosis	0.00109	0.00282	CcSEcCtD
Conivaptan—Infection—Estropipate—osteoporosis	0.00109	0.0028	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Ibandronate—osteoporosis	0.00109	0.0028	CcSEcCtD
Conivaptan—Malnutrition—Ethinyl Estradiol—osteoporosis	0.00109	0.0028	CcSEcCtD
Conivaptan—Hypertension—Calcitriol—osteoporosis	0.00109	0.0028	CcSEcCtD
Conivaptan—Constipation—Etidronic acid—osteoporosis	0.00108	0.00279	CcSEcCtD
Conivaptan—Cardiac disorder—Pamidronate—osteoporosis	0.00107	0.00277	CcSEcCtD
Conivaptan—Nervous system disorder—Estropipate—osteoporosis	0.00107	0.00277	CcSEcCtD
Conivaptan—Infection—Alendronate—osteoporosis	0.00107	0.00276	CcSEcCtD
Conivaptan—Dry mouth—Ibandronate—osteoporosis	0.00107	0.00276	CcSEcCtD
Conivaptan—Mental disorder—Risedronate—osteoporosis	0.00107	0.00275	CcSEcCtD
Conivaptan—Skin disorder—Estropipate—osteoporosis	0.00106	0.00274	CcSEcCtD
Conivaptan—Malnutrition—Risedronate—osteoporosis	0.00106	0.00273	CcSEcCtD
Conivaptan—Infection—Raloxifene—osteoporosis	0.00105	0.00272	CcSEcCtD
Conivaptan—Angiopathy—Pamidronate—osteoporosis	0.00105	0.00271	CcSEcCtD
Conivaptan—Dry mouth—Calcitriol—osteoporosis	0.00105	0.0027	CcSEcCtD
Conivaptan—Urinary tract disorder—Zoledronate—osteoporosis	0.00104	0.00269	CcSEcCtD
Conivaptan—Mediastinal disorder—Pamidronate—osteoporosis	0.00104	0.00269	CcSEcCtD
Conivaptan—Infection—Ibandronate—osteoporosis	0.00104	0.00269	CcSEcCtD
Conivaptan—Feeling abnormal—Etidronic acid—osteoporosis	0.00104	0.00269	CcSEcCtD
Conivaptan—Oedema peripheral—Zoledronate—osteoporosis	0.00104	0.00269	CcSEcCtD
Conivaptan—Nervous system disorder—Raloxifene—osteoporosis	0.00104	0.00268	CcSEcCtD
Conivaptan—Urethral disorder—Zoledronate—osteoporosis	0.00104	0.00267	CcSEcCtD
Conivaptan—Skin disorder—Raloxifene—osteoporosis	0.00103	0.00266	CcSEcCtD
Conivaptan—Nervous system disorder—Ibandronate—osteoporosis	0.00103	0.00265	CcSEcCtD
Conivaptan—Skin disorder—Ibandronate—osteoporosis	0.00102	0.00263	CcSEcCtD
Conivaptan—Nausea—Ergocalciferol—osteoporosis	0.00101	0.00261	CcSEcCtD
Conivaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—CNR2—osteoporosis	0.00101	0.0132	CbGpPWpGaD
Conivaptan—Malnutrition—Pamidronate—osteoporosis	0.00101	0.0026	CcSEcCtD
Conivaptan—Erythema—Pamidronate—osteoporosis	0.00101	0.0026	CcSEcCtD
Conivaptan—AVPR2—GPCRs, Class A Rhodopsin-like—CNR2—osteoporosis	0.001	0.0131	CbGpPWpGaD
Conivaptan—Oedema peripheral—Conjugated Estrogens—osteoporosis	0.001	0.00259	CcSEcCtD
Conivaptan—Skin disorder—Calcitriol—osteoporosis	0.000998	0.00257	CcSEcCtD
Conivaptan—Insomnia—Estropipate—osteoporosis	0.00099	0.00255	CcSEcCtD
Conivaptan—Cardiac disorder—Zoledronate—osteoporosis	0.000981	0.00253	CcSEcCtD
Conivaptan—Anaemia—Risedronate—osteoporosis	0.00098	0.00253	CcSEcCtD
Conivaptan—AVPR2—G alpha (s) signalling events—ADCY5—osteoporosis	0.000961	0.0126	CbGpPWpGaD
Conivaptan—Angiopathy—Zoledronate—osteoporosis	0.000959	0.00247	CcSEcCtD
Conivaptan—Insomnia—Raloxifene—osteoporosis	0.000959	0.00247	CcSEcCtD
Conivaptan—Mediastinal disorder—Zoledronate—osteoporosis	0.000953	0.00246	CcSEcCtD
Conivaptan—Insomnia—Ibandronate—osteoporosis	0.00095	0.00245	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Estropipate—osteoporosis	0.000945	0.00244	CcSEcCtD
Conivaptan—Cardiac disorder—Conjugated Estrogens—osteoporosis	0.000945	0.00244	CcSEcCtD
Conivaptan—Pollakiuria—Estradiol—osteoporosis	0.00094	0.00242	CcSEcCtD
Conivaptan—Constipation—Estropipate—osteoporosis	0.000936	0.00241	CcSEcCtD
Conivaptan—Pain—Estropipate—osteoporosis	0.000936	0.00241	CcSEcCtD
Conivaptan—Anaemia—Pamidronate—osteoporosis	0.000931	0.0024	CcSEcCtD
Conivaptan—Insomnia—Calcitriol—osteoporosis	0.00093	0.0024	CcSEcCtD
Conivaptan—Mental disorder—Zoledronate—osteoporosis	0.000926	0.00239	CcSEcCtD
Conivaptan—Angiopathy—Conjugated Estrogens—osteoporosis	0.000924	0.00238	CcSEcCtD
Conivaptan—Pain—Alendronate—osteoporosis	0.000922	0.00238	CcSEcCtD
Conivaptan—Constipation—Alendronate—osteoporosis	0.000922	0.00238	CcSEcCtD
Conivaptan—Malnutrition—Zoledronate—osteoporosis	0.000921	0.00237	CcSEcCtD
Conivaptan—Erythema—Zoledronate—osteoporosis	0.000921	0.00237	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—osteoporosis	0.000919	0.00237	CcSEcCtD
Conivaptan—Hyperglycaemia—Estradiol—osteoporosis	0.000918	0.00237	CcSEcCtD
Conivaptan—Mediastinal disorder—Conjugated Estrogens—osteoporosis	0.000918	0.00237	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Raloxifene—osteoporosis	0.000916	0.00236	CcSEcCtD
Conivaptan—Hypertension—Risedronate—osteoporosis	0.000915	0.00236	CcSEcCtD
Conivaptan—Pneumonia—Estradiol—osteoporosis	0.000913	0.00235	CcSEcCtD
Conivaptan—Infestation NOS—Estradiol—osteoporosis	0.000908	0.00234	CcSEcCtD
Conivaptan—Infestation—Estradiol—osteoporosis	0.000908	0.00234	CcSEcCtD
Conivaptan—Pain—Raloxifene—osteoporosis	0.000907	0.00234	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Ibandronate—osteoporosis	0.000906	0.00234	CcSEcCtD
Conivaptan—Constipation—Ibandronate—osteoporosis	0.000898	0.00231	CcSEcCtD
Conivaptan—Pain—Ibandronate—osteoporosis	0.000898	0.00231	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.000896	0.00231	CcSEcCtD
Conivaptan—Pruritus—Etidronic acid—osteoporosis	0.000895	0.00231	CcSEcCtD
Conivaptan—Mental disorder—Conjugated Estrogens—osteoporosis	0.000892	0.0023	CcSEcCtD
Conivaptan—Feeling abnormal—Alendronate—osteoporosis	0.000889	0.00229	CcSEcCtD
Conivaptan—Erythema—Conjugated Estrogens—osteoporosis	0.000886	0.00228	CcSEcCtD
Conivaptan—Malnutrition—Conjugated Estrogens—osteoporosis	0.000886	0.00228	CcSEcCtD
Conivaptan—Dry mouth—Risedronate—osteoporosis	0.000883	0.00228	CcSEcCtD
Conivaptan—Urinary tract infection—Estradiol—osteoporosis	0.000882	0.00227	CcSEcCtD
Conivaptan—Infection—Ethinyl Estradiol—osteoporosis	0.000882	0.00227	CcSEcCtD
Conivaptan—Constipation—Calcitriol—osteoporosis	0.000879	0.00227	CcSEcCtD
Conivaptan—Pain—Calcitriol—osteoporosis	0.000879	0.00227	CcSEcCtD
Conivaptan—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.00087	0.00224	CcSEcCtD
Conivaptan—Hypertension—Pamidronate—osteoporosis	0.00087	0.00224	CcSEcCtD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	0.000866	0.0113	CbGpPWpGaD
Conivaptan—Diarrhoea—Etidronic acid—osteoporosis	0.000866	0.00223	CcSEcCtD
Conivaptan—Haematuria—Estradiol—osteoporosis	0.000866	0.00223	CcSEcCtD
Conivaptan—Body temperature increased—Estropipate—osteoporosis	0.000865	0.00223	CcSEcCtD
Conivaptan—Feeling abnormal—Ibandronate—osteoporosis	0.000865	0.00223	CcSEcCtD
Conivaptan—Skin disorder—Ethinyl Estradiol—osteoporosis	0.000862	0.00222	CcSEcCtD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	0.00086	0.0112	CbGpPWpGaD
Conivaptan—Infection—Risedronate—osteoporosis	0.00086	0.00222	CcSEcCtD
Conivaptan—Body temperature increased—Alendronate—osteoporosis	0.000852	0.0022	CcSEcCtD
Conivaptan—Anaemia—Zoledronate—osteoporosis	0.000851	0.00219	CcSEcCtD
Conivaptan—Nervous system disorder—Risedronate—osteoporosis	0.000848	0.00219	CcSEcCtD
Conivaptan—Skin disorder—Risedronate—osteoporosis	0.00084	0.00217	CcSEcCtD
Conivaptan—Body temperature increased—Raloxifene—osteoporosis	0.000838	0.00216	CcSEcCtD
Conivaptan—Body temperature increased—Ibandronate—osteoporosis	0.00083	0.00214	CcSEcCtD
Conivaptan—Confusional state—Pamidronate—osteoporosis	0.000829	0.00214	CcSEcCtD
Conivaptan—Infection—Pamidronate—osteoporosis	0.000817	0.00211	CcSEcCtD
Conivaptan—Body temperature increased—Calcitriol—osteoporosis	0.000812	0.00209	CcSEcCtD
Conivaptan—Nervous system disorder—Pamidronate—osteoporosis	0.000807	0.00208	CcSEcCtD
Conivaptan—Urinary tract disorder—Estradiol—osteoporosis	0.000805	0.00207	CcSEcCtD
Conivaptan—Vomiting—Etidronic acid—osteoporosis	0.000805	0.00207	CcSEcCtD
Conivaptan—Oedema peripheral—Estradiol—osteoporosis	0.000803	0.00207	CcSEcCtD
Conivaptan—Urethral disorder—Estradiol—osteoporosis	0.000799	0.00206	CcSEcCtD
Conivaptan—Hypertension—Zoledronate—osteoporosis	0.000795	0.00205	CcSEcCtD
Conivaptan—Headache—Etidronic acid—osteoporosis	0.000793	0.00204	CcSEcCtD
Conivaptan—Insomnia—Risedronate—osteoporosis	0.000783	0.00202	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000778	0.00201	CcSEcCtD
Conivaptan—Pruritus—Estropipate—osteoporosis	0.000775	0.002	CcSEcCtD
Conivaptan—Hypotension—Pamidronate—osteoporosis	0.000769	0.00198	CcSEcCtD
Conivaptan—Dry mouth—Zoledronate—osteoporosis	0.000766	0.00198	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000766	0.00197	CcSEcCtD
Conivaptan—Pruritus—Alendronate—osteoporosis	0.000763	0.00197	CcSEcCtD
Conivaptan—Constipation—Ethinyl Estradiol—osteoporosis	0.000759	0.00196	CcSEcCtD
Conivaptan—Confusional state—Zoledronate—osteoporosis	0.000758	0.00195	CcSEcCtD
Conivaptan—Cardiac disorder—Estradiol—osteoporosis	0.000756	0.00195	CcSEcCtD
Conivaptan—Nausea—Etidronic acid—osteoporosis	0.000752	0.00194	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000749	0.00193	CcSEcCtD
Conivaptan—Diarrhoea—Estropipate—osteoporosis	0.000749	0.00193	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Risedronate—osteoporosis	0.000747	0.00193	CcSEcCtD
Conivaptan—Infection—Zoledronate—osteoporosis	0.000746	0.00192	CcSEcCtD
Conivaptan—Insomnia—Pamidronate—osteoporosis	0.000744	0.00192	CcSEcCtD
Conivaptan—Pruritus—Ibandronate—osteoporosis	0.000743	0.00191	CcSEcCtD
Conivaptan—Pain—Risedronate—osteoporosis	0.00074	0.00191	CcSEcCtD
Conivaptan—Constipation—Risedronate—osteoporosis	0.00074	0.00191	CcSEcCtD
Conivaptan—Angiopathy—Estradiol—osteoporosis	0.000739	0.00191	CcSEcCtD
Conivaptan—Diarrhoea—Alendronate—osteoporosis	0.000738	0.0019	CcSEcCtD
Conivaptan—Nervous system disorder—Zoledronate—osteoporosis	0.000737	0.0019	CcSEcCtD
Conivaptan—Mediastinal disorder—Estradiol—osteoporosis	0.000734	0.00189	CcSEcCtD
Conivaptan—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000731	0.00188	CcSEcCtD
Conivaptan—Skin disorder—Zoledronate—osteoporosis	0.00073	0.00188	CcSEcCtD
Conivaptan—AVPR1A—GPCR downstream signaling—PTH1R—osteoporosis	0.000728	0.00952	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—CALCR—osteoporosis	0.000728	0.00952	CbGpPWpGaD
Conivaptan—Pruritus—Calcitriol—osteoporosis	0.000727	0.00187	CcSEcCtD
Conivaptan—Diarrhoea—Raloxifene—osteoporosis	0.000726	0.00187	CcSEcCtD
Conivaptan—AVPR2—GPCR downstream signaling—PTH1R—osteoporosis	0.000723	0.00946	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—CALCR—osteoporosis	0.000723	0.00946	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—ANXA2—osteoporosis	0.00072	0.00941	CbGpPWpGaD
Conivaptan—Infection—Conjugated Estrogens—osteoporosis	0.000719	0.00185	CcSEcCtD
Conivaptan—Diarrhoea—Ibandronate—osteoporosis	0.000718	0.00185	CcSEcCtD
Conivaptan—Mental disorder—Estradiol—osteoporosis	0.000714	0.00184	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Pamidronate—osteoporosis	0.00071	0.00183	CcSEcCtD
Conivaptan—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000709	0.00183	CcSEcCtD
Conivaptan—Erythema—Estradiol—osteoporosis	0.000709	0.00183	CcSEcCtD
Conivaptan—Malnutrition—Estradiol—osteoporosis	0.000709	0.00183	CcSEcCtD
Conivaptan—AVPR2—G alpha (s) signalling events—POMC—osteoporosis	0.000707	0.00924	CbGpPWpGaD
Conivaptan—Pain—Pamidronate—osteoporosis	0.000703	0.00181	CcSEcCtD
Conivaptan—Constipation—Pamidronate—osteoporosis	0.000703	0.00181	CcSEcCtD
Conivaptan—Diarrhoea—Calcitriol—osteoporosis	0.000703	0.00181	CcSEcCtD
Conivaptan—Skin disorder—Conjugated Estrogens—osteoporosis	0.000703	0.00181	CcSEcCtD
Conivaptan—Hypotension—Zoledronate—osteoporosis	0.000702	0.00181	CcSEcCtD
Conivaptan—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000701	0.00181	CcSEcCtD
Conivaptan—Vomiting—Estropipate—osteoporosis	0.000696	0.00179	CcSEcCtD
Conivaptan—Headache—Estropipate—osteoporosis	0.000686	0.00177	CcSEcCtD
Conivaptan—Vomiting—Alendronate—osteoporosis	0.000686	0.00177	CcSEcCtD
Conivaptan—Body temperature increased—Risedronate—osteoporosis	0.000684	0.00176	CcSEcCtD
Conivaptan—Insomnia—Zoledronate—osteoporosis	0.000679	0.00175	CcSEcCtD
Conivaptan—Feeling abnormal—Pamidronate—osteoporosis	0.000678	0.00175	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—PTH—osteoporosis	0.000677	0.00885	CbGpPWpGaD
Conivaptan—Hypotension—Conjugated Estrogens—osteoporosis	0.000676	0.00174	CcSEcCtD
Conivaptan—Headache—Alendronate—osteoporosis	0.000676	0.00174	CcSEcCtD
Conivaptan—Vomiting—Raloxifene—osteoporosis	0.000674	0.00174	CcSEcCtD
Conivaptan—AVPR2—GPCR ligand binding—PTH—osteoporosis	0.000672	0.00879	CbGpPWpGaD
Conivaptan—Vomiting—Ibandronate—osteoporosis	0.000667	0.00172	CcSEcCtD
Conivaptan—Headache—Raloxifene—osteoporosis	0.000664	0.00171	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—CALCR—osteoporosis	0.000661	0.00865	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—PTH1R—osteoporosis	0.000661	0.00865	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—CNR2—osteoporosis	0.00066	0.00863	CbGpPWpGaD
Conivaptan—Headache—Ibandronate—osteoporosis	0.000658	0.0017	CcSEcCtD
Conivaptan—AVPR2—Signaling by GPCR—PTH1R—osteoporosis	0.000657	0.00859	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—CALCR—osteoporosis	0.000657	0.00859	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—CNR2—osteoporosis	0.000655	0.00857	CbGpPWpGaD
Conivaptan—Insomnia—Conjugated Estrogens—osteoporosis	0.000654	0.00169	CcSEcCtD
Conivaptan—Vomiting—Calcitriol—osteoporosis	0.000653	0.00168	CcSEcCtD
Conivaptan—Nausea—Estropipate—osteoporosis	0.00065	0.00168	CcSEcCtD
Conivaptan—Body temperature increased—Pamidronate—osteoporosis	0.00065	0.00168	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000649	0.00167	CcSEcCtD
Conivaptan—Headache—Calcitriol—osteoporosis	0.000644	0.00166	CcSEcCtD
Conivaptan—Pain—Zoledronate—osteoporosis	0.000642	0.00166	CcSEcCtD
Conivaptan—Constipation—Zoledronate—osteoporosis	0.000642	0.00166	CcSEcCtD
Conivaptan—Nausea—Alendronate—osteoporosis	0.00064	0.00165	CcSEcCtD
Conivaptan—Nausea—Raloxifene—osteoporosis	0.00063	0.00162	CcSEcCtD
Conivaptan—Pruritus—Ethinyl Estradiol—osteoporosis	0.000628	0.00162	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000625	0.00161	CcSEcCtD
Conivaptan—Nausea—Ibandronate—osteoporosis	0.000624	0.00161	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—WNT1—osteoporosis	0.00062	0.00811	CbGpPWpGaD
Conivaptan—Feeling abnormal—Zoledronate—osteoporosis	0.000619	0.0016	CcSEcCtD
Conivaptan—Constipation—Conjugated Estrogens—osteoporosis	0.000619	0.00159	CcSEcCtD
Conivaptan—Pain—Conjugated Estrogens—osteoporosis	0.000619	0.00159	CcSEcCtD
Conivaptan—AVPR2—GPCR ligand binding—WNT1—osteoporosis	0.000616	0.00805	CbGpPWpGaD
Conivaptan—Hypertension—Estradiol—osteoporosis	0.000612	0.00158	CcSEcCtD
Conivaptan—Pruritus—Risedronate—osteoporosis	0.000612	0.00158	CcSEcCtD
Conivaptan—Nausea—Calcitriol—osteoporosis	0.00061	0.00157	CcSEcCtD
Conivaptan—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000607	0.00157	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.0006	0.00155	CcSEcCtD
Conivaptan—Body temperature increased—Zoledronate—osteoporosis	0.000594	0.00153	CcSEcCtD
Conivaptan—Diarrhoea—Risedronate—osteoporosis	0.000592	0.00153	CcSEcCtD
Conivaptan—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—osteoporosis	0.000591	0.00773	CbGpPWpGaD
Conivaptan—Dry mouth—Estradiol—osteoporosis	0.000591	0.00152	CcSEcCtD
Conivaptan—Confusional state—Estradiol—osteoporosis	0.000584	0.0015	CcSEcCtD
Conivaptan—Pruritus—Pamidronate—osteoporosis	0.000582	0.0015	CcSEcCtD
Conivaptan—AVPR1A—GPCR downstream signaling—MGLL—osteoporosis	0.000579	0.00757	CbGpPWpGaD
Conivaptan—Infection—Estradiol—osteoporosis	0.000575	0.00148	CcSEcCtD
Conivaptan—AVPR2—GPCR downstream signaling—MGLL—osteoporosis	0.000574	0.00751	CbGpPWpGaD
Conivaptan—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000572	0.00147	CcSEcCtD
Conivaptan—Nervous system disorder—Estradiol—osteoporosis	0.000568	0.00146	CcSEcCtD
Conivaptan—Vomiting—Ethinyl Estradiol—osteoporosis	0.000564	0.00145	CcSEcCtD
Conivaptan—Diarrhoea—Pamidronate—osteoporosis	0.000563	0.00145	CcSEcCtD
Conivaptan—Skin disorder—Estradiol—osteoporosis	0.000562	0.00145	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—PTHLH—osteoporosis	0.000561	0.00734	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—PTHLH—osteoporosis	0.000557	0.00728	CbGpPWpGaD
Conivaptan—Headache—Ethinyl Estradiol—osteoporosis	0.000556	0.00143	CcSEcCtD
Conivaptan—Vomiting—Risedronate—osteoporosis	0.00055	0.00142	CcSEcCtD
Conivaptan—Headache—Risedronate—osteoporosis	0.000542	0.0014	CcSEcCtD
Conivaptan—Pruritus—Zoledronate—osteoporosis	0.000532	0.00137	CcSEcCtD
Conivaptan—Nausea—Ethinyl Estradiol—osteoporosis	0.000527	0.00136	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—MGLL—osteoporosis	0.000525	0.00687	CbGpPWpGaD
Conivaptan—Insomnia—Estradiol—osteoporosis	0.000524	0.00135	CcSEcCtD
Conivaptan—Vomiting—Pamidronate—osteoporosis	0.000523	0.00135	CcSEcCtD
Conivaptan—AVPR2—Signaling by GPCR—MGLL—osteoporosis	0.000522	0.00682	CbGpPWpGaD
Conivaptan—Headache—Pamidronate—osteoporosis	0.000515	0.00133	CcSEcCtD
Conivaptan—Diarrhoea—Zoledronate—osteoporosis	0.000514	0.00132	CcSEcCtD
Conivaptan—Nausea—Risedronate—osteoporosis	0.000514	0.00132	CcSEcCtD
Conivaptan—Pruritus—Conjugated Estrogens—osteoporosis	0.000512	0.00132	CcSEcCtD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—POMC—osteoporosis	0.000506	0.00661	CbGpPWpGaD
Conivaptan—AVPR2—Peptide ligand-binding receptors—POMC—osteoporosis	0.000502	0.00657	CbGpPWpGaD
Conivaptan—Gastrointestinal disorder—Estradiol—osteoporosis	0.0005	0.00129	CcSEcCtD
Conivaptan—Pain—Estradiol—osteoporosis	0.000495	0.00128	CcSEcCtD
Conivaptan—Constipation—Estradiol—osteoporosis	0.000495	0.00128	CcSEcCtD
Conivaptan—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000495	0.00128	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—CALCA—osteoporosis	0.000494	0.00646	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—CALCA—osteoporosis	0.00049	0.00641	CbGpPWpGaD
Conivaptan—Nausea—Pamidronate—osteoporosis	0.000489	0.00126	CcSEcCtD
Conivaptan—Vomiting—Zoledronate—osteoporosis	0.000478	0.00123	CcSEcCtD
Conivaptan—Feeling abnormal—Estradiol—osteoporosis	0.000477	0.00123	CcSEcCtD
Conivaptan—Headache—Zoledronate—osteoporosis	0.000471	0.00121	CcSEcCtD
Conivaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.000469	0.00614	CbGpPWpGaD
Conivaptan—CYP3A4—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.000463	0.00606	CbGpPWpGaD
Conivaptan—Vomiting—Conjugated Estrogens—osteoporosis	0.00046	0.00119	CcSEcCtD
Conivaptan—Body temperature increased—Estradiol—osteoporosis	0.000458	0.00118	CcSEcCtD
Conivaptan—Headache—Conjugated Estrogens—osteoporosis	0.000453	0.00117	CcSEcCtD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—osteoporosis	0.000447	0.00585	CbGpPWpGaD
Conivaptan—Nausea—Zoledronate—osteoporosis	0.000446	0.00115	CcSEcCtD
Conivaptan—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—osteoporosis	0.000442	0.00578	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—SOST—osteoporosis	0.000432	0.00565	CbGpPWpGaD
Conivaptan—Nausea—Conjugated Estrogens—osteoporosis	0.00043	0.00111	CcSEcCtD
Conivaptan—AVPR2—Signaling Pathways—SOST—osteoporosis	0.000429	0.00561	CbGpPWpGaD
Conivaptan—Pruritus—Estradiol—osteoporosis	0.00041	0.00106	CcSEcCtD
Conivaptan—Diarrhoea—Estradiol—osteoporosis	0.000396	0.00102	CcSEcCtD
Conivaptan—AVPR1A—Signaling Pathways—CALCR—osteoporosis	0.000391	0.00511	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PTH1R—osteoporosis	0.000391	0.00511	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PTH1R—osteoporosis	0.000388	0.00507	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CALCR—osteoporosis	0.000388	0.00507	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—PTH—osteoporosis	0.000383	0.005	CbGpPWpGaD
Conivaptan—CYP3A4—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000381	0.00498	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—PTH—osteoporosis	0.00038	0.00497	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—CNR2—osteoporosis	0.000373	0.00488	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—CNR2—osteoporosis	0.00037	0.00484	CbGpPWpGaD
Conivaptan—Vomiting—Estradiol—osteoporosis	0.000368	0.000949	CcSEcCtD
Conivaptan—Headache—Estradiol—osteoporosis	0.000363	0.000935	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—PTH—osteoporosis	0.000347	0.00454	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—PTH—osteoporosis	0.000345	0.00451	CbGpPWpGaD
Conivaptan—Nausea—Estradiol—osteoporosis	0.000344	0.000886	CcSEcCtD
Conivaptan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.00034	0.00444	CbGpPWpGaD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000339	0.00444	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—CNR2—osteoporosis	0.000339	0.00443	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000337	0.00441	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—CNR2—osteoporosis	0.000336	0.0044	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—WNT1—osteoporosis	0.000318	0.00416	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—PTHLH—osteoporosis	0.000317	0.00415	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—WNT1—osteoporosis	0.000316	0.00413	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—PTHLH—osteoporosis	0.000315	0.00412	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—MGLL—osteoporosis	0.00031	0.00406	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—MGLL—osteoporosis	0.000308	0.00403	CbGpPWpGaD
Conivaptan—CYP3A4—Tryptophan metabolism—CYP19A1—osteoporosis	0.000305	0.00399	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—LRP5—osteoporosis	0.000303	0.00396	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—LRP5—osteoporosis	0.000301	0.00393	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—LRP6—osteoporosis	0.00029	0.00379	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—PTHLH—osteoporosis	0.000288	0.00376	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—LRP6—osteoporosis	0.000288	0.00376	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—PTHLH—osteoporosis	0.000286	0.00374	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—CALCA—osteoporosis	0.000279	0.00365	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—CALCA—osteoporosis	0.000277	0.00362	CbGpPWpGaD
Conivaptan—AVPR2—Transmembrane transport of small molecules—ADCY5—osteoporosis	0.00027	0.00353	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—POMC—osteoporosis	0.000258	0.00338	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—POMC—osteoporosis	0.000257	0.00335	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—CALCA—osteoporosis	0.000253	0.00331	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—CALCA—osteoporosis	0.000252	0.00329	CbGpPWpGaD
Conivaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000247	0.00323	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—TLN1—osteoporosis	0.000245	0.0032	CbGpPWpGaD
Conivaptan—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000243	0.00318	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—TLN1—osteoporosis	0.000243	0.00318	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—P4HB—osteoporosis	0.000211	0.00276	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—P4HB—osteoporosis	0.000209	0.00274	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PTH—osteoporosis	0.000205	0.00268	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PTH—osteoporosis	0.000204	0.00266	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—CYP27A1—osteoporosis	0.000202	0.00264	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—RAP1A—osteoporosis	0.000202	0.00264	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—RAP1A—osteoporosis	0.0002	0.00262	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CNR2—osteoporosis	0.0002	0.00262	CbGpPWpGaD
Conivaptan—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.0002	0.00261	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—CYP27A1—osteoporosis	0.000199	0.00261	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	0.000199	0.0026	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CNR2—osteoporosis	0.000199	0.0026	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—ADCY5—osteoporosis	0.000199	0.0026	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—ADCY5—osteoporosis	0.000197	0.00258	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—NFATC1—osteoporosis	0.000197	0.00257	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—NFATC1—osteoporosis	0.000195	0.00255	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—DKK1—osteoporosis	0.000195	0.00255	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—DKK1—osteoporosis	0.000194	0.00253	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—WNT1—osteoporosis	0.000188	0.00246	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—WNT1—osteoporosis	0.000187	0.00244	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—FGA—osteoporosis	0.000183	0.00239	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—FGA—osteoporosis	0.000182	0.00237	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—ADCY5—osteoporosis	0.00018	0.00236	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—ADCY5—osteoporosis	0.000179	0.00234	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PTHLH—osteoporosis	0.00017	0.00222	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—BMP2—osteoporosis	0.00017	0.00222	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PTHLH—osteoporosis	0.000169	0.00221	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—BMP2—osteoporosis	0.000169	0.00221	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—FGB—osteoporosis	0.000166	0.00218	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—FGB—osteoporosis	0.000165	0.00216	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PSMA2—osteoporosis	0.000161	0.0021	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PSMA5—osteoporosis	0.000161	0.0021	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PSMA2—osteoporosis	0.000159	0.00209	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PSMA5—osteoporosis	0.000159	0.00209	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—CALCA—osteoporosis	0.00015	0.00196	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—CALCA—osteoporosis	0.000149	0.00194	CbGpPWpGaD
Conivaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	0.000148	0.00194	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—POMC—osteoporosis	0.000146	0.00191	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—POMC—osteoporosis	0.000145	0.0019	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—KL—osteoporosis	0.000136	0.00178	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—KL—osteoporosis	0.000135	0.00177	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—POMC—osteoporosis	0.000133	0.00173	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—POMC—osteoporosis	0.000132	0.00172	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—IL6R—osteoporosis	0.000129	0.00169	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—IL6R—osteoporosis	0.000128	0.00168	CbGpPWpGaD
Conivaptan—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	0.00012	0.00157	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—ADCY5—osteoporosis	0.000106	0.00139	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	0.000106	0.00139	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—ADCY5—osteoporosis	0.000106	0.00138	CbGpPWpGaD
Conivaptan—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	0.000105	0.00137	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—SPP1—osteoporosis	0.000103	0.00135	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—SPP1—osteoporosis	0.000102	0.00134	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—IRS2—osteoporosis	9.32e-05	0.00122	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—IRS2—osteoporosis	9.25e-05	0.00121	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—LEP—osteoporosis	9.12e-05	0.00119	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—LEP—osteoporosis	9.05e-05	0.00118	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—ESR1—osteoporosis	8.7e-05	0.00114	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—ESR1—osteoporosis	8.64e-05	0.00113	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—IRS1—osteoporosis	8.13e-05	0.00106	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—IRS1—osteoporosis	8.08e-05	0.00106	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—POMC—osteoporosis	7.83e-05	0.00102	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—POMC—osteoporosis	7.78e-05	0.00102	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—IL6R—osteoporosis	7.64e-05	0.000999	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—IL6R—osteoporosis	7.59e-05	0.000992	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—IGF1—osteoporosis	7.53e-05	0.000985	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—IGF1—osteoporosis	7.48e-05	0.000978	CbGpPWpGaD
Conivaptan—CYP3A4—Biological oxidations—POMC—osteoporosis	6.38e-05	0.000835	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—FDPS—osteoporosis	6.02e-05	0.000787	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PKM—osteoporosis	6.02e-05	0.000787	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—IL6—osteoporosis	5.76e-05	0.000753	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—IL6—osteoporosis	5.72e-05	0.000748	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GPD2—osteoporosis	5.71e-05	0.000746	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PGLS—osteoporosis	5.71e-05	0.000746	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ATIC—osteoporosis	5.22e-05	0.000683	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PNP—osteoporosis	5.22e-05	0.000683	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—MYC—osteoporosis	4.53e-05	0.000592	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—TGFB1—osteoporosis	4.52e-05	0.000591	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—MYC—osteoporosis	4.5e-05	0.000588	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—TGFB1—osteoporosis	4.48e-05	0.000586	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—OXCT1—osteoporosis	4.44e-05	0.00058	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CA2—osteoporosis	4.44e-05	0.00058	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—MGLL—osteoporosis	4.32e-05	0.000566	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—IDH2—osteoporosis	3.68e-05	0.000481	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CYP27A1—osteoporosis	3.46e-05	0.000452	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—IL6—osteoporosis	3.4e-05	0.000445	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—IL6—osteoporosis	3.38e-05	0.000442	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ACP5—osteoporosis	3.36e-05	0.00044	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—TPI1—osteoporosis	3.13e-05	0.000409	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—P4HB—osteoporosis	2.94e-05	0.000384	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GAPDH—osteoporosis	2.89e-05	0.000377	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—RAP1A—osteoporosis	2.81e-05	0.000368	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ENO1—osteoporosis	2.27e-05	0.000297	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PSMA2—osteoporosis	2.24e-05	0.000293	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PSMA5—osteoporosis	2.24e-05	0.000293	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CYP19A1—osteoporosis	1.82e-05	0.000238	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ADCY5—osteoporosis	1.48e-05	0.000194	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—GPX1—osteoporosis	1.48e-05	0.000193	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—MTHFR—osteoporosis	1.36e-05	0.000178	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—POMC—osteoporosis	1.09e-05	0.000143	CbGpPWpGaD
